Analogic (ALOG) 10-Q 10 Dec 14 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Oct. 31, 2014	Dec. 03, 2014
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Oct-14	'
Document Fiscal Year Focus	'2015	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'ALOG	'
Entity Registrant Name	'ANALOGIC CORP	'
Entity Central Index Key	'0000006284	'
Current Fiscal Year End Date	'--07-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	12,373,402

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Oct. 31, 2014	Jul. 31, 2014
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$116,443	$114,540
Accounts receivable, net of allowance for doubtful accounts of $835 and $800 as of October 31, 2014 and July 31, 2014, respectively	85,961	106,436
Inventory	136,570	124,777
Refundable and deferred income taxes	17,519	18,599
Other current assets	9,635	9,422
Total current assets	366,128	373,774
Property, plant, and equipment, net	112,156	114,165
Intangible assets, net	56,116	57,366
Goodwill	57,589	56,955
Deferred income taxes	6,626	7,475
Other assets	4,701	4,607
Total Assets	603,316	614,342
Current liabilities:	'	'
Accounts payable	34,111	37,241
Accrued employee compensation and benefits	16,849	16,305
Accrued warranty	6,185	5,968
Accrued restructuring charges	2,309	3,431
Deferred revenue	8,846	10,761
Customer deposits	2,953	3,046
Other current liabilities	7,041	7,761
Total current liabilities	78,294	84,513
Long-term liabilities:	'	'
Accrued income taxes	5,301	5,211
Deferred income taxes	1,548	2,657
Other long-term liabilities	9,651	9,381
Total long-term liabilities	16,500	17,249
Guarantees, commitments, and contingencies (Note 15)	'	'
Stockholders' equity:	'	'
Common stock, $0.05 par value; 30,000,000 shares authorized and 12,374,805 shares issued and outstanding as of October 31, 2014; 30,000,000 shares authorized and 12,372,992 shares issued and outstanding as of July 31, 2014	618	619
Capital in excess of par value	126,062	125,679
Retained earnings	377,667	378,477
Accumulated other comprehensive income	4,175	7,805
Total stockholders' equity	508,522	512,580
Total Liabilities and Stockholders' Equity	$603,316	$614,342

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Oct. 31, 2014	Jul. 31, 2014
In Thousands, except Share data, unless otherwise specified
Accounts receivable, allowance for doubtful accounts	$835	$800
Common stock, par value	$0.05	$0.05
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	12,374,805	12,372,992
Common stock, shares outstanding	12,374,805	12,372,992

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Oct. 31, 2014	Oct. 31, 2013
Net Revenue:	'	'
Product	$116,935	$108,454
Engineering	1,381	1,628
Total net revenue	118,316	110,082
Cost of sales:	'	'
Product	65,138	65,626
Engineering	1,179	1,520
Total cost of sales	66,317	67,146
Gross profit	51,999	42,936
Operating expenses:	'	'
Research and product development	17,369	18,854
Selling and marketing	15,509	14,570
General and administrative	14,222	14,916
Restructuring	-58	-39
Total operating expenses	47,042	48,301
Income (loss) from operations	4,957	-5,365
Other income (expense), net	118	-421
Income (loss) before income taxes	5,075	-5,786
Provision for (benefit from) income taxes	1,421	-2,011
Net income (loss)	$3,654	($3,775)
Net income (loss) per common share:	'	'
Basic	$0.29	($0.30)
Diluted	$0.29	($0.30)
Weighted average shares outstanding:	'	'
Basic	12,407	12,443
Diluted	12,570	12,443
Dividends declared and paid per share:	$0.10	$0.10

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Loss) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2014	Oct. 31, 2013
Net income (loss)	$3,654	($3,775)
Other comprehensive income, net of tax:	'	'
Foreign currency translation adjustment, net of tax	-3,630	1,057
Unrealized gains on foreign currency forward contracts, net of tax	'	18
Total other comprehensive (loss) income, net of tax	-3,630	1,075
Total comprehensive income (loss)	$24	($2,700)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2014	Oct. 31, 2013
OPERATING ACTIVITIES	'	'
Net income (loss)	$3,654	($3,775)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:	'	'
Provision for deferred income taxes	603	2,673
Depreciation and amortization	5,651	5,390
Share-based compensation expense	2,592	2,735
Excess tax benefit from share-based compensation	-180	-3,064
Write-down of inventory to net realizable value	1,213	300
Provision for doubtful accounts, net of recovery	35	-7
Loss on investment	'	484
(Gain) loss on sale of property, plant and equipment	-35	13
Net changes in operating assets and liabilities, exclusive of acquisition related assets and liabilities:	'	'
Accounts receivable	19,554	26,599
Inventory	-13,485	-2,612
Other current assets	-620	-606
Accounts payable	-3,171	397
Accrued liabilities	-791	-9,733
Customer deposits	-81	21
Deferred revenue	-1,884	1,475
Accrued income taxes	627	-10,126
Other liabilities	328	492
NET CASH FLOWS PROVIDED BY OPERATING ACTIVITIES	14,010	10,656
INVESTING ACTIVITIES	'	'
Additions to property, plant, and equipment	-2,665	-4,163
Acquisition of business, net of cash acquired	-1,600	-10,561
Purchases of marketable securities in Rabbi Trust under the Non Qualified Deferred Compensation Plan	-200	'
Proceeds from the sale of property, plant, and equipment	127	45
NET CASH FLOWS USED IN INVESTING ACTIVITIES	-4,338	-14,679
FINANCING ACTIVITIES	'	'
Issuance of stock pursuant to exercise of stock options, employee stock purchase plan, restricted stock plans, and non-employee director stock plan	152	3,848
Shares repurchased for taxes for vested employee restricted stock grants	-1,605	-6,085
Excess tax benefit from share-based compensation	180	3,064
Repurchase of common stock	-3,682	-3,731
Dividends paid to shareholders	-1,384	-1,243
NET CASH FLOWS USED IN FINANCING ACTIVITIES	-6,339	-4,147
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	-1,430	213
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	1,903	-7,957
CASH AND CASH EQUIVALENTS, BEGINNING OF THE PERIOD	114,540	113,033
CASH AND CASH EQUIVALENTS, END OF THE PERIOD	$116,443	$105,076

Business

Business	3 Months Ended
	Oct. 31, 2014
Business	'
	1. Business
	Company
	Throughout this Quarterly Report on Form 10-Q, unless the context states otherwise, the words “we,” “us,” “our” and “Analogic” refer to Analogic Corporation and all of its subsidiaries taken as a whole, and “our board of directors” refers to the board of directors of Analogic Corporation.
	Basis of Presentation
	Our unaudited consolidated financial statements presented herein have been prepared pursuant to the rules of the United States Securities and Exchange Commission, or SEC, for quarterly reports on Form 10-Q. Preparing financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. We report our financial condition and results of operations on a fiscal year basis ending on July 31st of each year.
	In our opinion, the accompanying unaudited consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary for a fair statement of the results for all interim periods presented. These statements should be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended July 31, 2014, or fiscal year 2014, included in our Annual Report on Form 10-K as filed with the SEC on September 26, 2014. The year-end balance sheet data was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles, or GAAP in the United States of America.
	Consolidation
	The unaudited consolidated financial statements presented herein include our accounts and those of our subsidiaries, all of which are wholly owned. Investments in companies in which ownership interests range from 10 to 50 percent and for which we exercise significant influence over the investee’s operating and financial policies, are accounted for using the equity method. All intercompany accounts and transactions have been eliminated in consolidation.
	In determining whether we are the primary beneficiary of an entity and therefore required to consolidate, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We have not been required to consolidate the activity of any entity due to these considerations.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	3 Months Ended
	Oct. 31, 2014
Recent Accounting Pronouncements	'
	2. Recent Accounting Pronouncements
	Recently adopted
	Foreign currency matters
	In March 2013, the Financial Accounting Standards Board, or FASB, issued an update which amends guidance on foreign currency matters and consolidations to address diversity in practice related to the release of cumulative translation adjustments, or CTA, into earnings upon the occurrence of certain de-recognition events. The update reflects a compromise between the CTA release guidance included within foreign currency matters and the loss of control concepts included within consolidation guidance. It precludes the release of CTA for de-recognition events that occur within a foreign entity, unless such events represent a complete or substantially complete liquidation of the foreign entity. De-recognition events related to investments in a foreign entity result in the release of all CTA related to the derecognized foreign entity, even when a non-controlling financial interest is retained. The update also amends guidance on business combinations and for transactions that result in a company obtaining control of a business in a step acquisition by increasing an investment in a foreign entity from one accounted for under the equity method to one accounted for as a consolidated investment. This update should be applied prospectively and prior periods should not be adjusted. The update is effective for us beginning on August 1, 2014. The adoption of this standard did not have a material impact on our Consolidated Financial Statements.
	Not yet effective
	Revenue from contracts with customers
	In May 2014, the FASB issued an update which provides guidance for revenue recognition. This update affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. This update will supersede existing revenue recognition requirement and most industry-specific guidance. This update also supersedes some cost guidance, including revenue recognition guidance for construction-type and production-type contracts. The update’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under today’s guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. This update should be applied modified retrospectively or restrospectively. This update will be effective for us in the first quarter of fiscal year 2018. Early adoption is not permitted. We are currently evaluating the impact of the adoption of this update on our Consolidated Financial Statements.

Business_Combinations

Business Combinations	3 Months Ended
	Oct. 31, 2014
Business Combinations	'
	3. Business Combinations
	Pathfinder Therapeutics, Inc., or Pathfinder
	On October 28, 2014, we acquired certain assets and assumed liabilities related to the surgical planning and guidance business of Pathfinder Therapeutics, Inc. for $1.6 million paid in cash at the acquisition date. The acquisition has been accounted for as an acquisition of a business.
	The following table summarized the purchase price allocation based on preliminary estimates of the fair values of the separately identifiable assets acquired and liabilities assumed as of the acquisition date. We continue to obtain information to complete our valuation of these accounts and the associated tax accounting:
	(in millions)
	Inventory and receivables				$	0.1
	Goodwill					0.6
	Intangible assets:
	Developed technology (estimated useful life of 10 years)		0.7
	Customer Relationships (estimated useful life of 2 years)		0.2
	Tradename (estimated useful life of 5 years)		0.1
	Total intangible assets					1
	Total assets acquired					1.7
	Accrued liabilities					(0.1	)
	Total liabilities assumed					(0.1	)
	Total purchase price				$	1.6
	We estimated the fair value of identifiable acquisition-related intangible assets primarily based on discounted cash flows projections that will arise from these assets. We use significant judgment with regard to assumptions used in the determination of fair value such as discount rates and the determination of the estimated useful lives of the intangible assets.
	The total weighted average amortization period for the intangible assets is approximately 10 years. Goodwill associated with the acquisition was primarily attributable to the opportunities from the addition of Pathfinder’s product portfolio and technology which complement our suite of products. The goodwill from this acquisition will be deductible for tax purposes over the statutory 15 year period.
	During the three months ended October 31, 2014, we incurred acquisition costs of approximately $0.1 million which consisted primarily of legal and due diligence expenses that are included in our general and administrative expenses in our consolidated statement of operations.
	The pro forma financial information for the three months ended October 31, 2014 and 2013, including revenue and net income, is deemed immaterial.
	PocketSonics, Inc., or PocketSonics
	In April 2010, we entered into an agreement with PocketSonics, Inc., or PocketSonics, a privately held ultrasound technology company based in Charlottesville, Virginia, which granted us an exclusive license to certain ultrasound technology owned or controlled by PocketSonics and a ten percent (10%) equity interest in PocketSonics. The equity investment was recorded as in-process research and development, or IPR&D, of $1.9 million. Since that time, we have collaborated with PocketSonics to develop patented ultrasound technology to enable the acceleration of high acuity guided procedures to lower cost point-of-care settings and other technical applications. On September 20, 2013, we acquired all of the remaining stock of PocketSonics. The purchase price includes base consideration of $11.1 million paid in cash at closing, fair value of contingent consideration of $1.9 million, and revaluation of our initial equity investment. We undertook this acquisition to further strengthen our competitive position in procedure guidance for point-of-care and other advanced guidance applications. The acquisition was funded from our existing cash on hand and has been accounted for as an acquisition of a business.
	We finalized the purchase accounting for the PocketSonics acquisition during the fiscal year 2014. The following table summarizes the fair values of the separately identifiable assets acquired and liabilities assumed as of September 20, 2013:
	(in millions)
	Cash	$	0.5
	Goodwill		6.9
	IPR&D		11.5
	Total assets acquired		18.9
	Accounts payable and accrued expenses		(0.3	)
	Deferred taxes		(4.1	)
	Total liabilities assumed		(4.4	)
	Total purchase price	$	14.5
	In determining the fair value, we considered, among other factors, market participants’ intentions to use the acquired assets and the historical and estimated future demand for PocketSonics products and services. We recognized an IPR&D asset of $11.5 million. The fair value of the asset was determined by a probability adjusted cash flow analysis. In May 2014, we determined that the IPR&D was completed and reclassified as developed technology that is being amortized over its estimated useful life of 10 years.
	In connection with this acquisition, we recorded a fair value contingent consideration obligation of $1.9 million, with potential exposure of up to $3.0 million payable upon the achievement of certain milestones relating to the PocketSonics technology. The contingent earn out payments to the sellers of PocketSonics would be payable upon commercial launch and achievement of volume sales target as defined in the asset purchase agreement. The $1.9 million fair value was estimated through a valuation model that incorporates probability adjusted assumptions relating to the achievement of these milestones and the likelihood of us making payments. This fair value measurement is based upon significant inputs not observable in the market and therefore represents a Level 3 input measurement. Subsequent changes in the fair value of this obligation will be recognized as adjustments to the contingent consideration liability and reflected within our consolidated statement of operations within selling and marketing expenses. For additional information related to the fair value of this obligation, please refer to Note 7. Fair Value Measurements.
	We also recorded a goodwill asset of $6.9 million, representing the value of the opportunity of further strengthening our competitive position in procedure guidance for point-of-care and other advanced guidance applications. The goodwill will not be deductible for tax purposes.
	We recognized a loss of $0.5 million related to our 10% pre-acquisition equity interest, which is reflected as a component of other expense, net within our consolidated statement of operations for the three months ended October 31, 2013.
	During the three months ended October 31, 2013, we incurred acquisition costs of approximately $0.1 million which consisted primarily of legal and due diligence expenses that are included in our general and administrative expenses in our consolidated statement of operations.

Accounts_Receivable_Net

Accounts Receivable, Net	3 Months Ended
	Oct. 31, 2014
Accounts Receivable, Net	'
	4. Accounts Receivable, Net
	Our accounts receivable arise primarily from products sold and services provided in the U.S., Europe and Asia. The balance in accounts receivable represents the amount due from our domestic and foreign original equipment manufacturers, or OEM, customers, distributors and end users. The majority of our accounts receivable have standard payment terms that require payment within 30 days. We perform ongoing credit evaluations of our customers’ financial condition and continuously monitor collections and payments from our customers and maintain a provision for estimated credit losses based upon specific customer collection issues that have been identified. Amounts determined to be uncollectible are charged or written off against the reserve. To date, our historical write-offs of accounts receivable have been minimal.
	Our top ten customers combined accounted for approximately 64% and 62% of our total net revenue for the three months ended October 31, 2014 and 2013, respectively. Our customers, which individually accounted for 10% or more of our net revenue, are set forth in the table below:
			For the Three Months Ended
			October 31
			2014			2013
	Koninklijke Philips Electronics N.V., or Philips			11	%		17	%
	Siemens AG, or Siemens			13	%		10	%
	Toshiba Corporation, or Toshiba			13	%		*
	Note	(*): Total net revenue was less than 10% in this period.
	The following table summarizes our customers with net accounts receivable balances greater than or equal to 10% of our total net accounts receivable balance:
			As of			As of
			October 31,			July 31,
			2014			2014
	Philips			15	%		16	%
	L-3 Communications Security and Detection Systems, or L-3			14	%		16	%
	Toshiba			*			11	%
	Note	(*): Total net accounts receivable due from client was less than 10% in this period.

Inventory

Inventory	3 Months Ended
	Oct. 31, 2014
Inventory	'
	5. Inventory
	The components of inventory, net of allowance for obsolete, unmarketable or slow-moving inventories, are summarized as follows:
	(in millions)	As of		As of
		October 31,		July 31,
		2014		2014
	Raw materials	$	64.7	$	59.6
	Work in process		45.6		41.2
	Finished goods		26.3		24
	Total inventory	$	136.6	$	124.8

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	3 Months Ended
	Oct. 31, 2014
Goodwill and Other Intangible Assets	'
	6. Goodwill and Other Intangible Assets
	Goodwill
	The carrying value of our goodwill at October 31, 2014 and July 31, 2014 was $57.6 million and $57.0 million, respectively. The difference between the two periods relates to goodwill associated with the acquisition of Pathfinder of $0.6 million. Please refer to Note 3. Business Combinations for more information on the acquisition of Pathfinder.
	Intangible assets
	Intangible assets include the value assigned to intellectual property and other technology, patents, customer contracts and relationships, and trade names. The estimated useful lives for all of these intangible assets, excluding a trade name, as this is considered to have an indefinite life, are between 1 to 14 years. The carrying value of our indefinite lived intangible assets was $7.6 million at both October 31, 2014 and July 31, 2014.
	Intangible assets are summarized as follows:
					October 31, 2014						July 31, 2014
	(in millions)	Weighted-Average			Cost		Accumulated		Net		Cost		Accumulated		Net
		Amortization Period					Amortization						Amortization
	Developed technologies		10 years		$	30.2	$	9.8	$	20.4	$	29.6	$	9	$	20.6
	Customer relationships		13 years			44.1		16.4		27.7		43.9		15.1		28.8
	Trade names		3 years	*		8.6		0.6		8		8.5		0.5		8
	Total intangible assets				$	82.9	$	26.8	$	56.1	$	82	$	24.6	$	57.4
	* - $7.6 Million of Trade names are Non-amortizable
	Amortization expense related to acquired intangible assets was $2.2 million and $1.9 million for the three months ended October 31, 2014 and 2013, respectively.
	The estimated future amortization expenses related to intangible assets for each of the five succeeding fiscal years is expected to be as follows:
		Estimated
		future
		amortization
		expense
	2015 (remaining nine months)	$	6.6
	2016		7.9
	2017		7.2
	2018		6.2
	2019		5
	Thereafter		15.6
		$	48.5
	We performed the annual impairment test for our goodwill and other intangible assets with indefinite lives as of December 31, 2013 and concluded that there was no impairment.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Oct. 31, 2014
Fair Value Measurements	'
	7. Fair Value Measurements
	Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. We use a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
	Level 1 – Quoted prices in active markets for identical assets or liabilities.
	Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The following table provides the assets and liabilities carried at fair value and measured on a recurring basis at October 31, 2014 and July 31, 2014:
				Fair Value Measurements at October 31, 2014
	(in millions)	Total		Quoted		Significant		Significant
				Prices in		Other		Unobservable
				Active		Observable		Inputs
				Markets for		Inputs		(Level 3)
				Identical		(Level 2)
				Assets
				(Level 1)
	Assets
	Plan assets for deferred compensation	$	3.8	$	3.8	$	-	$	-
	Total assets at fair value	$	3.8	$	3.8	$	-	$	-
	Liabilities
	Contingent Consideration	$	2.1	$	-	$	-	$	2.1
	Total liabilities at fair value	$	2.1	$	-	$	-	$	2.1
				Fair Value Measurements at July 31, 2014
	(in millions)	Total		Quoted		Significant		Significant
				Prices in		Other		Unobservable
				Active		Observable		Inputs
				Markets for		Inputs		(Level 3)
				Identical		(Level 2)
				Assets
				(Level 1)
	Assets
	Plan assets for deferred compensation	$	3.6	$	3.6	$	-	$	-
	Total assets at fair value	$	3.6	$	3.6	$	-	$	-
	Liabilities
	Contingent Consideration	$	2.1	$	-	$	-	$	2.1
	Total liabilities at fair value	$	2.1	$	-	$	-	$	2.1
	Assets held in the deferred compensation plans will be used to pay benefits under our non-qualified deferred compensation plans. The investments primarily consist of mutual funds which are publicly traded on stock exchanges. Accordingly, the fair value of these assets are categorized as Level 1 within the fair value hierarchy.
	The fair value of our contingent consideration obligation is based on significant unobservable inputs, including management estimates and assumptions, and is measured based on the probability-weighted present value of the payments expected to be made. Accordingly, the fair value of this liability is categorized as Level 3 within the fair value hierarchy.
	The fair value of the contingent payments associated with the acquisition of PocketSonics was calculated utilizing 100% for the earn out associated with the Section 510(k) clearance obtained from the Food and Drug Administration, or FDA, on April 9, 2014 and the anticipation of commercial sales, as defined in the purchase agreement, in fiscal year 2015. Each quarter we revalue the contingent consideration obligations associated with the acquisition of PocketSonics to its then current fair value and record changes in the fair value to the Consolidated Statement of Operations. Changes in contingent consideration result from changes in the assumptions regarding probabilities of the estimated timing of launch, volume sales target, payments and the discount rate used to estimate the fair value of the liability. The assumptions used in estimating fair value require significant judgment. The use of different assumptions and judgments could result in a materially different estimate of fair value. There was no change in the fair value of our contingent consideration obligation during the three months ended October 31, 2014.

Common_Stock_Repurchases

Common Stock Repurchases	3 Months Ended
	Oct. 31, 2014
Common Stock Repurchases	'
	8. Common Stock Repurchases
	On June 2, 2014, our board of directors authorized the repurchase of up to $30.0 million of our common stock. Repurchases under this program will be funded by our available cash. The repurchase program does not have a fixed expiration date. During the three months ended October 31, 2014, we repurchased and retired 52,746 shares of common stock under this repurchase program for $3.7 million at an average purchase price of $69.78 per share. As of October 31, 2014, in total we have repurchased and retired 71,429 shares of common stock under this repurchase program for $5.1 million at an average purchase price of $71.46 per share.
	On December 8, 2011, we announced that our board of directors had authorized the repurchase of up to $30 million of our common stock. During the three months ended October 31, 2013, we repurchased and retired 46,638 shares of common stock under this repurchase program for $3.7 million at an average purchase price of $79.97 per share. The 2011 repurchase program was completed in the fourth quarter of fiscal year 2014. The cumulative shares that were repurchased and retired under the program were 415,768 shares of common stock for $30.0 million at an average price of $71.98 per share.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	3 Months Ended
	Oct. 31, 2014
Accumulated Other Comprehensive Income	'
	9. Accumulated Other Comprehensive Income
	Components of comprehensive income include net income and certain transactions that have generally been reported in the Consolidated Statements of Changes in Stockholders’ Equity. Other comprehensive income consists of reported foreign currency translation gains and losses (net of taxes), actuarial gains and losses on pension plan assets (net of taxes), and changes in the unrealized value on foreign currency forward contracts (net of taxes). Deferred taxes are not provided on cumulative translation adjustments where we expect earnings of a foreign subsidiary to be indefinitely reinvested. The income tax effect of currency translation adjustments related to foreign subsidiaries that are not considered indefinitely reinvested is recorded as a component of deferred taxes with an offset to other comprehensive income.
	The following table summarizes components of accumulated other comprehensive income as follows:
	(in millions)	Unrealized			Currency			Accumulated
		Gains			Translation			Other
		(Losses)  on			Adjustment			Comprehensive
		Pension Plan						Income
	Balance as of July 31, 2014	$	(3.6	)	$	11.4		$	7.8
	Pre-tax change before reclass to earnings		-			(3.5	)		(3.5	)
	Income tax benefit (provision)		-			(0.1	)		(0.1	)
	Balance as of October 31, 2014	$	(3.6	)	$	7.8		$	4.2
	The ineffective portion of the unrealized gains or losses on foreign currency forward contracts and unrealized gains or losses on currency translation are included in other expense, net on our consolidated statement of operations.

Sharebased_Compensation

Share-based Compensation	3 Months Ended
	Oct. 31, 2014
Share-based Compensation	'
	10. Share-based Compensation
	The following table presents share-based compensation expense included in our consolidated statements of operations:
			For the Three Months Ended
			October 31
	(in millions)		2014			2013
	Cost of product sales		$	0.2		$	0.2
	Cost of engineering sales			—			0.1
	Research and product development			0.7			0.6
	Selling and marketing			0.3			0.3
	General and administrative			1.4			1.5
	Total share-based compensation expense before tax			2.6			2.7
	Income tax effect			(0.8	)		(0.9	)
	Share-based compensation expense included in net income (loss)		$	1.8		$	1.8
	Stock options
	We estimate the fair value of stock options using the Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the exercise price of the award, the expected option term, the expected volatility of our stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and our expected annual dividend yield. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards.
	The fair value of each option grant was estimated on the grant date using the Black-Scholes valuation model with the following assumptions:
			For the Three Months Ended
			October 31
			2014			2013
	Expected option term in years (1)			5.31			5.37
	Expected volatility (2)			29.3	%		38.6	%
	Risk-free interest rate (3)			1.83	%		1.77	%
	Expected annual dividend yield (4)			0.56	%		0.52	%
	-1	The expected option term was estimated using historical data.
	-2	The expected volatility for each grant is determined based on the review of the average of historical daily price changes of our common stock over the expected option term.
	-3	The risk-free interest rate is determined based on the yield of the zero-coupon U.S. Treasury securities for a period that is commensurate with the expected term assumption.
	-4	The expected annual dividend yield is calculated by dividing the expected annual dividends by the stock price on the date of grant.
	The weighted average grant date fair value of stock options that were granted during the three months ended October 31, 2014 was $19.95. The weighted average grant date fair value of stock options that were granted during the three months ended October 31, 2013 was $27.54.
	The total intrinsic value of options exercised during the three months ended October 31, 2014 and 2013, was $0.1 million and $1.5 million, respectively, with intrinsic value defined as the difference between the market price on the date of exercise and the grant date exercise price.
	Restricted stock and restricted stock units
	We estimate the fair value of restricted stock and restricted stock units, or RSU’s, that vest based on service conditions using the quoted closing price of our common stock on the date of grant. Share-based compensation expense is recognized over each award’s vesting period on a straight-line basis for all awards with service conditions, while the graded vesting method applies to all awards with both service and performance conditions.
	For our non-GAAP earnings per share, or EPS, performance-based awards, the compensation cost is recognized over the performance period on a straight-line basis, net of forfeitures, because such awards vest only at the end of the performance period. The compensation cost is based on the number of shares that are deemed probable of vesting at the end of the three-year performance cycle. This probability assessment is done each quarter and changes in estimates can result in significant expense fluctuations due to the cumulative catch-up adjustment. We estimate the fair value of the non-GAAP EPS performance-based awards using the quoted closing price of our common stock on the date of grant.
	For our relative total shareholder return, or TSR, performance-based awards, which are based on market performance, the compensation cost is recognized over the performance period on a straight-line basis net of forfeitures, because the awards vest only at the end of the measurement period and the probability of actual shares expected to be earned is considered in the grant date valuation. As a result, the expense is not adjusted to reflect the actual shares earned. We estimate the fair value of the TSR performance-based awards using the Monte-Carlo simulation model.
	We granted 27,065 TSR and 34,850 non-GAAP EPS performance-based awards during the three months ended October 31, 2014. We granted 27,355 TSR and 35,562 non-GAAP EPS performance-based awards during the three months ended October 31, 2013. The fair value of our TSR performance-based awards at the date of grant was estimated using the Monte-Carlo simulation model with the following assumptions:
			For the Three Months Ended
			October 31
			2014			2013
	Stock Price (1)		$	71.09		$	77.08
	Expected volatility (2)			29.4	%		27.6	%
	Risk-free interest rate (3)			1.01	%		0.82	%
	Expected annual dividend yield (4)			0	%		0	%
	-1	The stock price is the closing price of our common stock on the date of grant.
	-2	The expected volatility for each grant is determined based on the historical volatility for the peer group companies and our common stock over a period equal to the remaining term of the performance period from the date of grant for all awards.
	-3	The risk-free interest rate is determined based on the yield of zero-coupon U.S. Treasury securities for a period that is commensurate with the expected term assumption.
	-4	Dividends are considered reinvested when calculating TSR. The dividend yield is therefore considered to be 0%.
	The weighted average grant date fair value of time-based restricted stock awards that were granted during the three months ended October 31, 2014 and 2013 was $71.09 and $76.99, respectively. The weighted average grant date fair value of performance-based restricted stock awards that were granted during the three months ended October 31, 2014 and 2013 was $78.25 and $93.76, respectively.
	The total fair value of restricted stock shares that vested during the three months ended October 31, 2014 and 2013 was $5.2 million and $19.8 million, respectively.
	As of October 31, 2014, the unrecognized compensation cost, net of estimated forfeitures, related to unvested stock options and restricted stock was $17.0 million. This cost will be recognized over an estimated weighted average amortization period of 1.9 years and assumes most recent non-GAAP EPS forecast for the performance-based RSU’s.

Restructuring_Charges

Restructuring Charges	3 Months Ended
	Oct. 31, 2014
Restructuring Charges	'
	11. Restructuring Charges
	Fiscal Year 2014 Restructuring Plan
	During the fourth quarter of fiscal year 2014, we implemented our fiscal year 2014 restructuring plan to improve our operational effectiveness in Peabody, Massachusetts to better leverage core competencies across the business. We incurred pre-tax charges of $2.9 million, primarily relating to severance and personnel related costs for 48 involuntarily terminated employees. We expect that the restructuring plan will be completed during fiscal year 2015.
	Fiscal Year 2013 Restructuring Plan
	In May 2013, we announced our fiscal year 2013 restructuring plan and incurred pre-tax charges of $4.0 million through October 31, 2014, primarily relating to severance and personnel related costs of 115 terminated employees, facility exit costs for the closure of the Ultrasonix sales subsidiary in Paris, France, and the closure of our ultrasound transducer operation in Englewood, Colorado as we consolidate our transducer operations in State College, Pennsylvania. This plan also includes activities to consolidate manufacturing and certain support functions currently conducted in our Ultrasonix facility in Vancouver, Canada with our other facilities, as well as optimization of our operations in Montreal, Canada and Peabody, Massachusetts. During the three months ended October 31, 2014, we incurred $(0.1) million related to the Englewood, Colorado facility.
	Current Period Activity
	The following table summarizes accrued restructuring activities during the first quarter of fiscal year 2015:
	(In millions)		Employee			Facility			Acquisition			Total
			Severance			Exit			Related
			and Benefits (A)			Costs (B)			Charges (B)
	Balance at July 31, 2014		$	2.9		$	0.8		$	0.1		$	3.8
	Adjustments			-			(0.1	)		-			(0.1	)
	Cash payments			(0.9	)		(0.1	)		(0.1	)		(1.1	)
	Balance at October 31, 2014		$	2.0		$	0.6		$	-		$	2.6
	(A)	All activity during the period pertains to the 2014 Restructuring Plan.
	(B)	All activity pertains to the 2013 Restructuring Plan.
	The following table summarizes charges related to the accrued restructuring activities during the first quarter of fiscal year 2014:
	(in millions)		Employee			Facility			Acquisition			Total (A)
			Severance			Exit			Related
			and Benefits			Costs			Charges
	Balance at July 31, 2013		$	1.8		$	0.2		$	0.8		$	2.8
	Restructuring Charge			0.2			-			0.1			0.3
	Adjustments			(0.2	)		-			(0.1	)		(0.3	)
	Cash payments			(0.5	)		-			(0.1	)		(0.6	)
	Balance at October 31, 2013		$	1.3		$	0.2		$	0.7		$	2.2
	(A)	All activity during the period pertains to the 2013 Restructuring Plan.
	Accrued Restructuring Charges are comprised on the Consolidated Balance Sheets in the following location:
	(in millions)		October 31,			July 31,
			2014			2014
	Accrued Restructuring Charges		$	2.3		$	3.4
	Other long-term liabilities			0.3			0.4
	Restructuring and related charges		$	2.6		$	3.8
	Restructuring costs, including actions associated with acquisitions, by segment for fiscal years 2015 and 2014 are as follows:
			Three Months Ended
			October 31,
	(in millions)		2014			2013
	Medical Imaging		$	-		$	(0.1	)
	Ultrasound			(0.1	)		0.1
	Security Technology			-			-
	Total restructuring and related charges		$	(0.1	)	$	-

Net_income_loss_per_share

Net income (loss) per share	3 Months Ended
	Oct. 31, 2014
Net income (loss) per share	'
	12. Net income (loss) per share
	Basic net income (loss) per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed using the sum of the weighted average number of common shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common stock, including unvested restricted stock and the assumed exercise of stock options using the treasury stock method.
	Basic and diluted net income (loss) per share are calculated as follows:
			For the Three Months Ended
			October 31
	(in millions, except share data)		2014		2013
	Net income (loss)		$	3.7	$	(3.8	)
	Weighted average number of common shares			12,407		12,443
	outstanding-basic (000’s)
	Effect of dilutive securities:
	Stock options and restricted stock units (000’s)			163		-
	Weighted average number of common shares		$	12,570	$	12,443
	outstanding-diluted (000’s)
	Basic net income (loss) per share:		$	0.29	($	0.3	)
	Diluted net income (loss) per share:		$	0.29	($	0.3	)
	Anti-dilutive shares related to outstanding stock options and unvested restricted stock (000’s) (A)			255		546
	(A)	These shares related to outstanding stock options and unvested restricted stock were not included in our calculations of diluted earnings per share, as the effect of including them would be anti-dilutive.

Income_Taxes

Income Taxes	3 Months Ended
	Oct. 31, 2014
Income Taxes	'
	13. Income Taxes
	The following table presents the provision for (benefit from) income taxes and our effective tax rate for the three months ended October 31, 2014 and 2013:
		Three Months Ended
		October 31,
	(in millions)	2014			2013
	Provision for (benefit from) income taxes	$	1.4		$	(2.0	)
	Effective tax rate		28	%		35	%
	The effective income tax rate on continuing operations is based upon the estimated income for the year, the composition of the income in different countries, and adjustments, if any, in the applicable quarterly periods for the potential tax consequences, benefits, resolutions of tax audits or other tax contingencies.
	Our effective tax rate for the three months ended October 31, 2014 was lower than the statutory rate of 35% due primarily to income generated outside the United States in countries which carry lower tax rates.
	We are subject to U.S. Federal income tax as well as the income tax of multiple state and foreign jurisdictions. As of October 31, 2014, we have concluded all U.S. Federal income tax matters through the year ended July 31, 2010.
	We accrue interest and, if applicable, penalties for any uncertain tax positions. This interest and penalty expense is treated as a component of income tax expense. At October 31, 2014 and July 31, 2014, we had approximately $0.7 million and $0.6 million, respectively, accrued for interest and penalties on unrecognized tax benefits.
	We have $6.9 million of unrecognized tax benefits for uncertain tax positions and $0.7 million of related accrued interest and penalties. We are unable to reasonably estimate the amount and period in which these liabilities might be paid.

Segment_Information

Segment Information	3 Months Ended
	Oct. 31, 2014
Segment Information	'
	14. Segment Information:
	Our business is strategically aligned into three segments: Medical Imaging, Ultrasound, and Security and Detection. Our business segments are described as follows:
		•		Medical Imaging primarily includes systems and subsystems for Computed Tomography, or CT, and Magnetic Resonance Imaging, or MRI medical imaging equipment as well as state-of-the-art, selenium-based detectors for screening of breast cancer and other diagnostic applications in mammography.
		•		Ultrasound includes ultrasound systems and transducers primarily in the urology, surgery, anesthesia, and point-of-care markets.
		•		Security and Detection, formerly known as Security Technology, includes advanced threat detection systems utilizing our expertise in CT and advanced detection technology primarily used in checked baggage screening at airports worldwide.
	The tables below present information about our reportable segments:
			For the Three Months Ended
			October 31
	(in millions)		2014			2013
	Product Revenue:
	Medical Imaging		$	66.3		$	59.2
	Ultrasound			37.3			34.7
	Security and Detection			13.3			14.6
	Total product revenue		$	116.9		$	108.5
	Engineering Revenue:
	Medical Imaging		$	0.4		$	1
	Ultrasound			0.5			-
	Security and Detection			0.5			0.6
	Total engineering revenue		$	1.4		$	1.6
	Net Revenue:
	Medical Imaging		$	66.7		$	60.2
	Ultrasound			37.8			34.7
	Security and Detection			13.8			15.2
	Total net revenue		$	118.3		$	110.1
	Income (loss) from operations
	Medical Imaging		$	7.4		$	(0.5	)
	Ultrasound			(3.0	)		(4.0	)
	Security and Detection			0.6			(0.9	)
	Total income (loss) from operations			5			(5.4	)
	Total other income (expense), net			0.1			(0.4	)
	Income (loss) from operations before income taxes		$	5.1		$	(5.8	)
			As of			As of
			October 31,			July 31,
	(in millions)		2014			2014
	Identifiable assets by segment:
	Medical Imaging		$	207.2		$	218.5
	Ultrasound			240.3			235.5
	Security and Detection			34.4			35
	Total reportable segment assets			481.9			489
	Corporate assets (A)			121.4			125.3
	Total assets		$	603.3		$	614.3
			As of			As of
			October 31,			July 31,
	(in millions)		2014			2014
	Goodwill by segment:
	Medical Imaging		$	1.9		$	1.9
	Ultrasound			55.1			55.1
	Security and Detection (B)			0.6			-
	Total reportable segment goodwill		$	57.6		$	57
	(A)	Includes cash and cash equivalents of $57.1 million and $60.9 million as of October 31, 2014 and July 31, 2014, respectively.
	(B)	Includes goodwill related to the acquisition of Pathfinder.

Guarantees_Commitments_and_Con

Guarantees, Commitments and Contingencies	3 Months Ended
	Oct. 31, 2014
Guarantees, Commitments and Contingencies	'
	15. Guarantees, Commitments and Contingencies:
	Guarantees and Indemnification Obligations
	Our standard OEM and supply agreements entered in the ordinary course of business typically contain an indemnification provision pursuant to which we indemnify, hold harmless, and agree to reimburse the indemnified party for losses suffered or incurred by the indemnified party in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to our products. Such provisions generally survive termination or expiration of the agreements. The potential amount of future payments we could be required to make under these indemnification provisions is, in some instances, unlimited. Our costs to defend lawsuits or settle claims related to these indemnification agreements have been insignificant to date. As a result, we believe that our estimated exposure on these agreements is currently minimal. Accordingly, we have no liabilities recorded for these agreements as of October 31, 2014.
	Generally, we warrant that our products will perform in all material respects in accordance with our standard published specifications in effect at the time of delivery of the products to the customer for a period ranging from 12 to 60 months from the date of delivery. We provide for the estimated cost of product and service warranties based on specific warranty claims, claim history, and engineering estimates, where applicable.
	The following table presents our product warranty liability:
			As of
			October 31,
	(in millions)		2014
	Product warranty liability, beginning balance		$	6
	Provision			1.3
	Settlements made in cash or in kind during the period			(1.1	)
	Product warranty liability, ending balance		$	6.2
	At October 31, 2014 and July 31, 2014, we had deferred revenue for product extended warranty contracts of $6.6 million and $7.4 million, respectively.
	Revolving Credit Agreements
	On October 11, 2011, we entered into a five-year, revolving credit agreement, or Credit Agreement with the financial institutions identified therein as lenders, which included Santander Bank, TD Bank, N.A., and HSBC Bank USA, National Association. The Credit Agreement provides $100.0 million in available credit and expires on October 10, 2016, when all outstanding borrowings will be payable in full. The credit facility does not require amortization of principal and may be reduced before maturity in whole or in part at our option without penalty.
	Borrowings under the Credit Agreement may be used for general corporate purposes, including permitted acquisitions. The amount of available credit can be increased under specified circumstances up to $150.0 million in aggregate. We are the sole borrower under the Credit Agreement. The obligations under the new credit facility are guaranteed by our material domestic subsidiaries and are supported by a pledge of 65% of the capital stock and equity equivalents of our principal international subsidiaries.
	Interest rates on borrowings outstanding under the credit facility would range from 1.25% to 2.00% above the London Interbank Offered Rate, or LIBOR, or, at our option would range from 0.00% to 1.00% above the defined base rate, in each case based upon our leverage ratio. A quarterly commitment fee ranging from 0.20% to 0.35% per annum is applicable on the undrawn portion of the credit facility, based upon our leverage ratio.
	The Credit Agreement limits our ability to, among other things: incur additional indebtedness; incur liens or guarantee obligations; pay dividends or make other distributions; make investments; dispose of assets; and engage in transactions with affiliates except on an arms-length basis. In addition, the Credit Agreement requires us to maintain the following financial ratios:
		•		A leverage ratio, defined as consolidated funded indebtedness to consolidated trailing four quarters earnings before interest, taxes, depreciation, and amortization, or EBITDA, of no greater than 2.75:1.00 at any time; and
		•		An interest coverage ratio, defined as the ratio of consolidated trailing four quarters EBITDA to consolidated interest charges of no less than 3.00:1.00 at any time.
	As of October 31, 2014 our leverage ratio was .003 and our interest coverage ratio was not applicable as we had no attributable interest expense. As of October 31, 2014, we were in full compliance with all financial and operating covenants.
	Any failure to comply with the financial or operating covenants of the credit facility would prevent us from being able to borrow and would also constitute a default, permitting the lenders to, among other things, accelerate repayment of outstanding borrowings, including all accrued interest and fees, and to terminate the credit facility. A change in control of us, as defined in the Credit Agreement, would also constitute an event of default, permitting the lenders to accelerate repayment and terminate the Credit Agreement.
	In connection with entering into this facility, we incurred approximately $0.5 million of transactions costs, which are being expensed over the five-year life of the credit facility.
	As of October 31, 2014, we also had approximately $1.4 million in other revolving credit facilities with banks available for direct borrowings. We did not have any borrowing outstanding under our credit facilities at October 31, 2014 and July 31, 2014.
	Asset retirement obligations, or ARO
	As of October 31, 2014 and July 31, 2014, ARO for the estimated future costs associated with restoring our leased facilities were both $1.1 million and included in Other liabilities in our Consolidated Balance Sheet. During the three months ended October 31, 2014 and 2013, we recorded an insignificant amount of accretion and foreign currency translation related to ARO.
	Legal Claims
	We are subject to litigation, claims, investigations and audits arising from time to time in the ordinary course of our business. Although legal proceedings are inherently unpredictable, we believe that we have valid defenses with respect to those matters currently pending against us and intend to defend ourselves vigorously. The outcome of these matters, individually and in the aggregate, is not expected to have a material impact on our cash flows, results of operations, or financial position. In addition to litigation claims, investigations, and audits arising in the normal course of business, we are also subject to an investigation regarding our Danish subsidiary. Please refer to the following disclosure for more details regarding the investigation of our Danish subsidiary. We record losses when estimable and probable in accordance with U.S. GAAP.
	Investigation Regarding our Danish Subsidiary
	As initially disclosed in our Annual Report on Form 10-K for the fiscal year ended July 31, 2011, we identified certain transactions involving our Danish subsidiary BK Medical ApS, or BK Medical, and certain of its foreign distributors, with respect to which we have raised questions concerning compliance with law, including Danish law and the U.S. Foreign Corrupt Practices Act, and our business policies. These have included transactions in which the distributors paid BK Medical amounts in excess of amounts owed and BK Medical transferred the excess amounts, at the direction of the distributors, to third parties identified by the distributors. We have terminated the employment of certain BK Medical employees and have wound down the relationships with the BK Medical distributors that were involved in the transactions. We have concluded that the transactions identified to date have been properly accounted for in our reported financial statements in all material respects. However, we have been unable to ascertain with certainty the ultimate beneficiaries or the purpose of these transfers. We have voluntarily disclosed this matter to the Danish Government, the U.S. Department of Justice, or DOJ, and the SEC, and are cooperating with inquiries by the Danish Government, the DOJ and the SEC. We believe that the SEC and DOJ have substantially completed their investigation into the transactions at issue and that it is reasonably likely that one or both of these entities may seek to impose sanctions and/or penalties on us in connection with a resolution of their inquiries. We are unable to estimate the potential penalties and/or sanctions that may ultimately be assessed. During the three months ended October 31, 2014 and 2013, we incurred inquiry-related costs of approximately $0.8 million and $0.3 million, respectively, in connection with this matter.

Subsequent_Event

Subsequent Event	3 Months Ended
	Oct. 31, 2014
Subsequent Event	'
	16. Subsequent Event:
	We declared a dividend of $0.10 per share of common stock on December 5, 2014, which will be paid on January 2, 2015 to stockholders of record on December 19, 2014.

Business_Combinations_Tables

Business Combinations (Tables)	3 Months Ended
	Oct. 31, 2014
PocketSonics	'
Summary of Estimated Fair Values of Separately Identifiable Assets Acquired and Liabilities Assumed	'
	The following table summarizes the fair values of the separately identifiable assets acquired and liabilities assumed as of September 20, 2013:
	(in millions)
	Cash	$	0.5
	Goodwill		6.9
	IPR&D		11.5
	Total assets acquired		18.9
	Accounts payable and accrued expenses		(0.3	)
	Deferred taxes		(4.1	)
	Total liabilities assumed		(4.4	)
	Total purchase price	$	14.5
Pathfinder Therapeutics Inc	'
Summary of Estimated Fair Values of Separately Identifiable Assets Acquired and Liabilities Assumed	'
	The following table summarized the purchase price allocation based on preliminary estimates of the fair values of the separately identifiable assets acquired and liabilities assumed as of the acquisition date. We continue to obtain information to complete our valuation of these accounts and the associated tax accounting:
	(in millions)
	Inventory and receivables				$	0.1
	Goodwill					0.6
	Intangible assets:
	Developed technology (estimated useful life of 10 years)		0.7
	Customer Relationships (estimated useful life of 2 years)		0.2
	Tradename (estimated useful life of 5 years)		0.1
	Total intangible assets					1
	Total assets acquired					1.7
	Accrued liabilities					(0.1	)
	Total liabilities assumed					(0.1	)
	Total purchase price				$	1.6

Accounts_Receivable_Net_Tables

Accounts Receivable, Net (Tables)	3 Months Ended
	Oct. 31, 2014
Percentage of Net Product and Engineering Revenue from Major Customers	'
	Our customers, which individually accounted for 10% or more of our net revenue, are set forth in the table below:
			For the Three Months Ended
			October 31
			2014			2013
	Koninklijke Philips Electronics N.V., or Philips			11	%		17	%
	Siemens AG, or Siemens			13	%		10	%
	Toshiba Corporation, or Toshiba			13	%		*
	Note	(*): Total net revenue was less than 10% in this period.
Summary of Net Accounts Receivable Greater Than or Equal to 10% of Net Account Receivable Balance	'
	The following table summarizes our customers with net accounts receivable balances greater than or equal to 10% of our total net accounts receivable balance:
			As of			As of
			October 31,			July 31,
			2014			2014
	Philips			15	%		16	%
	L-3 Communications Security and Detection Systems, or L-3			14	%		16	%
	Toshiba			*			11	%
	Note	(*): Total net accounts receivable due from client was less than 10% in this period.

Inventory_Tables

Inventory (Tables)	3 Months Ended
	Oct. 31, 2014
Components of inventory, net	'
	The components of inventory, net of allowance for obsolete, unmarketable or slow-moving inventories, are summarized as follows:
	(in millions)	As of		As of
		October 31,		July 31,
		2014		2014
	Raw materials	$	64.7	$	59.6
	Work in process		45.6		41.2
	Finished goods		26.3		24
	Total inventory	$	136.6	$	124.8

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	3 Months Ended
	Oct. 31, 2014
Intangible Assets	'
	Intangible assets are summarized as follows:
					October 31, 2014						July 31, 2014
	(in millions)	Weighted-Average			Cost		Accumulated		Net		Cost		Accumulated		Net
		Amortization Period					Amortization						Amortization
	Developed technologies		10 years		$	30.2	$	9.8	$	20.4	$	29.6	$	9	$	20.6
	Customer relationships		13 years			44.1		16.4		27.7		43.9		15.1		28.8
	Trade names		3 years	*		8.6		0.6		8		8.5		0.5		8
	Total intangible assets				$	82.9	$	26.8	$	56.1	$	82	$	24.6	$	57.4
	* - $7.6 Million of Trade names are Non-amortizable
Estimated Future Amortization Expenses Related to Intangible Assets	'
	The estimated future amortization expenses related to intangible assets for each of the five succeeding fiscal years is expected to be as follows:
		Estimated
		future
		amortization
		expense
	2015 (remaining nine months)	$	6.6
	2016		7.9
	2017		7.2
	2018		6.2
	2019		5
	Thereafter		15.6
		$	48.5

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Oct. 31, 2014
Assets and Liabilities Carried at Fair Value Measured on Recurring Basis	'
	The following table provides the assets and liabilities carried at fair value and measured on a recurring basis at October 31, 2014 and July 31, 2014:
				Fair Value Measurements at October 31, 2014
	(in millions)	Total		Quoted		Significant		Significant
				Prices in		Other		Unobservable
				Active		Observable		Inputs
				Markets for		Inputs		(Level 3)
				Identical		(Level 2)
				Assets
				(Level 1)
	Assets
	Plan assets for deferred compensation	$	3.8	$	3.8	$	-	$	-
	Total assets at fair value	$	3.8	$	3.8	$	-	$	-
	Liabilities
	Contingent Consideration	$	2.1	$	-	$	-	$	2.1
	Total liabilities at fair value	$	2.1	$	-	$	-	$	2.1
				Fair Value Measurements at July 31, 2014
	(in millions)	Total		Quoted		Significant		Significant
				Prices in		Other		Unobservable
				Active		Observable		Inputs
				Markets for		Inputs		(Level 3)
				Identical		(Level 2)
				Assets
				(Level 1)
	Assets
	Plan assets for deferred compensation	$	3.6	$	3.6	$	-	$	-
	Total assets at fair value	$	3.6	$	3.6	$	-	$	-
	Liabilities
	Contingent Consideration	$	2.1	$	-	$	-	$	2.1
	Total liabilities at fair value	$	2.1	$	-	$	-	$	2.1

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Oct. 31, 2014
Changes in Accumulated Other Comprehensive Income	'
	The following table summarizes components of accumulated other comprehensive income as follows:
	(in millions)	Unrealized			Currency			Accumulated
		Gains			Translation			Other
		(Losses)  on			Adjustment			Comprehensive
		Pension Plan						Income
	Balance as of July 31, 2014	$	(3.6	)	$	11.4		$	7.8
	Pre-tax change before reclass to earnings		-			(3.5	)		(3.5	)
	Income tax benefit (provision)		-			(0.1	)		(0.1	)
	Balance as of October 31, 2014	$	(3.6	)	$	7.8		$	4.2

Sharebased_Compensation_Tables

Share-based Compensation (Tables)	3 Months Ended
	Oct. 31, 2014
Share-Based Compensation Expense	'
	The following table presents share-based compensation expense included in our consolidated statements of operations:
			For the Three Months Ended
			October 31
	(in millions)		2014			2013
	Cost of product sales		$	0.2		$	0.2
	Cost of engineering sales			—			0.1
	Research and product development			0.7			0.6
	Selling and marketing			0.3			0.3
	General and administrative			1.4			1.5
	Total share-based compensation expense before tax			2.6			2.7
	Income tax effect			(0.8	)		(0.9	)
	Share-based compensation expense included in net income (loss)		$	1.8		$	1.8
Fair Value of Option Grant Assumptions	'
	The fair value of each option grant was estimated on the grant date using the Black-Scholes valuation model with the following assumptions:
			For the Three Months Ended
			October 31
			2014			2013
	Expected option term in years (1)			5.31			5.37
	Expected volatility (2)			29.3	%		38.6	%
	Risk-free interest rate (3)			1.83	%		1.77	%
	Expected annual dividend yield (4)			0.56	%		0.52	%
	-1	The expected option term was estimated using historical data.
	-2	The expected volatility for each grant is determined based on the review of the average of historical daily price changes of our common stock over the expected option term.
	-3	The risk-free interest rate is determined based on the yield of the zero-coupon U.S. Treasury securities for a period that is commensurate with the expected term assumption.
	-4	The expected annual dividend yield is calculated by dividing the expected annual dividends by the stock price on the date of grant.
Fair Value of Awards Grant Assumptions	'
	The fair value of our TSR performance-based awards at the date of grant was estimated using the Monte-Carlo simulation model with the following assumptions:
			For the Three Months Ended
			October 31
			2014			2013
	Stock Price (1)		$	71.09		$	77.08
	Expected volatility (2)			29.4	%		27.6	%
	Risk-free interest rate (3)			1.01	%		0.82	%
	Expected annual dividend yield (4)			0	%		0	%
	-1	The stock price is the closing price of our common stock on the date of grant.
	-2	The expected volatility for each grant is determined based on the historical volatility for the peer group companies and our common stock over a period equal to the remaining term of the performance period from the date of grant for all awards.
	-3	The risk-free interest rate is determined based on the yield of zero-coupon U.S. Treasury securities for a period that is commensurate with the expected term assumption.
	-4	Dividends are considered reinvested when calculating TSR. The dividend yield is therefore considered to be 0%.

Restructuring_Charges_Tables

Restructuring Charges (Tables)	3 Months Ended
	Oct. 31, 2014
Summary of Accrued Restructuring Activities	'
	The following table summarizes accrued restructuring activities during the first quarter of fiscal year 2015:
	(In millions)		Employee			Facility			Acquisition			Total
			Severance			Exit			Related
			and Benefits (A)			Costs (B)			Charges (B)
	Balance at July 31, 2014		$	2.9		$	0.8		$	0.1		$	3.8
	Adjustments			-			(0.1	)		-			(0.1	)
	Cash payments			(0.9	)		(0.1	)		(0.1	)		(1.1	)
	Balance at October 31, 2014		$	2.0		$	0.6		$	-		$	2.6
	(A)	All activity during the period pertains to the 2014 Restructuring Plan.
	(B)	All activity pertains to the 2013 Restructuring Plan.
	The following table summarizes charges related to the accrued restructuring activities during the first quarter of fiscal year 2014:
	(in millions)		Employee			Facility			Acquisition			Total (A)
			Severance			Exit			Related
			and Benefits			Costs			Charges
	Balance at July 31, 2013		$	1.8		$	0.2		$	0.8		$	2.8
	Restructuring Charge			0.2			-			0.1			0.3
	Adjustments			(0.2	)		-			(0.1	)		(0.3	)
	Cash payments			(0.5	)		-			(0.1	)		(0.6	)
	Balance at October 31, 2013		$	1.3		$	0.2		$	0.7		$	2.2
	(A)	All activity during the period pertains to the 2013 Restructuring Plan.
Restructuring costs, including actions associated with acquisitions	'
Net Restructuring and Related Charges	'
	Restructuring costs, including actions associated with acquisitions, by segment for fiscal years 2015 and 2014 are as follows:
			Three Months Ended
			October 31,
	(in millions)		2014			2013
	Medical Imaging		$	-		$	(0.1	)
	Ultrasound			(0.1	)		0.1
	Security Technology			-			-
	Total restructuring and related charges		$	(0.1	)	$	-
Restructuring And Other Costs	'
Net Restructuring and Related Charges	'
	Accrued Restructuring Charges are comprised on the Consolidated Balance Sheets in the following location:
	(in millions)		October 31,			July 31,
			2014			2014
	Accrued Restructuring Charges		$	2.3		$	3.4
	Other long-term liabilities			0.3			0.4
	Restructuring and related charges		$	2.6		$	3.8

Net_income_loss_per_share_Tabl

Net income (loss) per share (Tables)	3 Months Ended
	Oct. 31, 2014
Computation of Basic and Diluted Net Income (Loss) Per Share	'
	Basic and diluted net income (loss) per share are calculated as follows:
			For the Three Months Ended
			October 31
	(in millions, except share data)		2014		2013
	Net income (loss)		$	3.7	$	(3.8	)
	Weighted average number of common shares			12,407		12,443
	outstanding-basic (000’s)
	Effect of dilutive securities:
	Stock options and restricted stock units (000’s)			163		-
	Weighted average number of common shares		$	12,570	$	12,443
	outstanding-diluted (000’s)
	Basic net income (loss) per share:		$	0.29	($	0.3	)
	Diluted net income (loss) per share:		$	0.29	($	0.3	)
	Anti-dilutive shares related to outstanding stock options and unvested restricted stock (000’s) (A)			255		546
	(A)	These shares related to outstanding stock options and unvested restricted stock were not included in our calculations of diluted earnings per share, as the effect of including them would be anti-dilutive.

Income_Taxes_Tables

Income Taxes (Tables)	3 Months Ended
	Oct. 31, 2014
Provision for (Benefit from) Income Taxes and Effective Tax Rate	'
	The following table presents the provision for (benefit from) income taxes and our effective tax rate for the three months ended October 31, 2014 and 2013:
		Three Months Ended
		October 31,
	(in millions)	2014			2013
	Provision for (benefit from) income taxes	$	1.4		$	(2.0	)
	Effective tax rate		28	%		35	%

Segment_Information_Tables

Segment Information (Tables)	3 Months Ended
	Oct. 31, 2014
Reportable Segment Information	'
	The tables below present information about our reportable segments:
			For the Three Months Ended
			October 31
	(in millions)		2014			2013
	Product Revenue:
	Medical Imaging		$	66.3		$	59.2
	Ultrasound			37.3			34.7
	Security and Detection			13.3			14.6
	Total product revenue		$	116.9		$	108.5
	Engineering Revenue:
	Medical Imaging		$	0.4		$	1
	Ultrasound			0.5			-
	Security and Detection			0.5			0.6
	Total engineering revenue		$	1.4		$	1.6
	Net Revenue:
	Medical Imaging		$	66.7		$	60.2
	Ultrasound			37.8			34.7
	Security and Detection			13.8			15.2
	Total net revenue		$	118.3		$	110.1
	Income (loss) from operations
	Medical Imaging		$	7.4		$	(0.5	)
	Ultrasound			(3.0	)		(4.0	)
	Security and Detection			0.6			(0.9	)
	Total income (loss) from operations			5			(5.4	)
	Total other income (expense), net			0.1			(0.4	)
	Income (loss) from operations before income taxes		$	5.1		$	(5.8	)
			As of			As of
			October 31,			July 31,
	(in millions)		2014			2014
	Identifiable assets by segment:
	Medical Imaging		$	207.2		$	218.5
	Ultrasound			240.3			235.5
	Security and Detection			34.4			35
	Total reportable segment assets			481.9			489
	Corporate assets (A)			121.4			125.3
	Total assets		$	603.3		$	614.3
			As of			As of
			October 31,			July 31,
	(in millions)		2014			2014
	Goodwill by segment:
	Medical Imaging		$	1.9		$	1.9
	Ultrasound			55.1			55.1
	Security and Detection (B)			0.6			-
	Total reportable segment goodwill		$	57.6		$	57
	(A)	Includes cash and cash equivalents of $57.1 million and $60.9 million as of October 31, 2014 and July 31, 2014, respectively.
	(B)	Includes goodwill related to the acquisition of Pathfinder.

Guarantees_Commitments_and_Con1

Guarantees, Commitments and Contingencies (Tables)	3 Months Ended
	Oct. 31, 2014
Product Warranty Liability	'
	The following table presents our product warranty liability:
		As of
		October 31,
	(in millions)	2014
	Product warranty liability, beginning balance	$	6
	Provision		1.3
	Settlements made in cash or in kind during the period		(1.1	)
	Product warranty liability, ending balance	$	6.2

Business_Additional_Informatio

Business - Additional Information (Detail)	Oct. 31, 2014
Minimum	'
Organization and Summary of Significant Accounting Policies Disclosure [Line Items]	'
Ownership interests	10.00%
Maximum	'
Organization and Summary of Significant Accounting Policies Disclosure [Line Items]	'
Ownership interests	50.00%

Business_Combinations_Addition

Business Combinations - Additional Information (Detail) (USD $)

3 Months Ended

0 Months Ended

3 Months Ended

1 Months Ended

0 Months Ended

3 Months Ended

Oct. 31, 2014

Oct. 31, 2013

Jul. 31, 2014

Oct. 31, 2014

Sep. 20, 2013

Oct. 31, 2013

Sep. 20, 2013

Apr. 30, 2010

Sep. 20, 2013

30-May-14

Sep. 20, 2013

Apr. 30, 2010

Oct. 28, 2014

Oct. 31, 2014

Maximum

PocketSonics

PocketSonics

PocketSonics

PocketSonics

PocketSonics

PocketSonics

PocketSonics

PocketSonics

Pathfinder Therapeutics Inc

Pathfinder Therapeutics Inc

Maximum

In-process research and development

In-process research and development

In-process research and development

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total purchase price

$1,600,000

$10,561,000

'

'

'

'

'

'

'

'

'

'

$1,600,000

'

Weighted average amortization period for intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

Business Acquisition, Goodwill Expected Tax Deductible Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'15 years

Acquisition related charges

'

'

'

'

'

100,000

'

'

'

'

'

'

'

100,000

Ownership interests

'

'

'

50.00%

'

'

'

10.00%

'

'

'

'

'

'

Amount of equity investment

'

'

'

'

'

'

'

'

'

'

'

1,900,000

'

'

Amount merger consideration paid

'

'

'

'

11,100,000

'

'

'

'

'

'

'

'

'

Contingent consideration

'

'

'

'

'

'

1,900,000

'

3,000,000

'

'

'

'

'

Intangible assets

'

'

'

'

'

'

'

'

'

'

11,500,000

'

'

1,000,000

Amortization period

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

Business acquisition, goodwill

57,589,000

'

56,955,000

'

'

'

6,900,000

'

'

'

'

'

'

600,000

Loss from pre-acquisition equity interest

'

'

'

'

'

$500,000

'

'

'

'

'

'

'

'

Summary_of_Estimated_Fair_Valu

Summary of Estimated Fair Values of Separately Identifiable Assets Acquired and Liabilities Assumed (Detail) (USD $)	Oct. 31, 2014	Jul. 31, 2014
Business Acquisition [Line Items]	'	'
Goodwill	$57,589,000	$56,955,000
Pathfinder Therapeutics Inc	'	'
Business Acquisition [Line Items]	'	'
Inventory and receivables	100,000	'
Goodwill	600,000	'
Intangible assets	1,000,000	'
Total assets acquired	1,700,000	'
Accrued liabilities	-100,000	'
Total liabilities assumed	-100,000	'
Total purchase price	1,600,000	'
Pathfinder Therapeutics Inc | Developed technologies	'	'
Business Acquisition [Line Items]	'	'
Intangible assets	700,000	'
Pathfinder Therapeutics Inc | Customer relationships	'	'
Business Acquisition [Line Items]	'	'
Intangible assets	200,000	'
Pathfinder Therapeutics Inc | Tradenames	'	'
Business Acquisition [Line Items]	'	'
Intangible assets	$100,000	'

Summary_of_Estimated_Fair_Valu1

Summary of Estimated Fair Values of Separately Identifiable Assets Acquired and Liabilities Assumed (Parenthetical) (Detail) (Pathfinder Therapeutics Inc)	3 Months Ended
	Oct. 31, 2014
Developed technologies	'
Business Acquisition [Line Items]	'
Weighted average useful life	'10 years
Customer relationships	'
Business Acquisition [Line Items]	'
Weighted average useful life	'2 years
Tradenames	'
Business Acquisition [Line Items]	'
Weighted average useful life	'5 years

Summary_of_Fair_Values_of_Sepa

Summary of Fair Values of Separately Identifiable Assets Acquired and Liabilities Assumed (Detail) (USD $)	Oct. 31, 2014	Jul. 31, 2014	Sep. 20, 2013	Sep. 20, 2013
			PocketSonics	PocketSonics
				In-process research and development
Business Acquisition [Line Items]	'	'	'	'
Cash	'	'	$500,000	'
Goodwill	57,589,000	56,955,000	6,900,000	'
Intangible assets	'	'	'	11,500,000
Total assets acquired	'	'	18,900,000	'
Accounts payable and accrued expenses	'	'	-300,000	'
Deferred taxes	'	'	-4,100,000	'
Total liabilities assumed	'	'	-4,400,000	'
Total purchase price	'	'	$14,500,000	'

Accounts_Receivable_Net_Additi

Accounts Receivable, Net - Additional Information (Detail) (Sales Revenue, Net, Largest customers)	3 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Sales Revenue, Net | Largest customers	'	'
Accounts Receivable [Line Items]	'	'
Percentage of total net revenue	64.00%	62.00%

Percentage_of_Net_Product_and_

Percentage of Net Product and Engineering Revenue from Major Customers (Detail) (Sales Revenue, Net, Largest customers)	3 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Concentration Risk [Line Items]	'	'
Percentage of net product and engineering revenue	64.00%	62.00%
Philips	'	'
Concentration Risk [Line Items]	'	'
Percentage of net product and engineering revenue	11.00%	17.00%
Siemens AG	'	'
Concentration Risk [Line Items]	'	'
Percentage of net product and engineering revenue	13.00%	10.00%
Toshiba	'	'
Concentration Risk [Line Items]	'	'
Percentage of net product and engineering revenue	13.00%	'	[1]
[1]	Total net revenue was less than 10% in this period.

Percentage_of_Net_Product_and_1

Percentage of Net Product and Engineering Revenue from Major Customers (Parenthetical) (Detail) (Largest customers, Sales Revenue, Net)	3 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Concentration Risk [Line Items]	'	'
Percentage of net product and engineering revenue	64.00%	62.00%
Toshiba	'	'
Concentration Risk [Line Items]	'	'
Percentage of net product and engineering revenue	13.00%	'	[1]
Maximum | Toshiba	'	'
Concentration Risk [Line Items]	'	'
Percentage of net product and engineering revenue	'	10.00%
[1]	Total net revenue was less than 10% in this period.

Summary_of_Net_Accounts_Receiv

Summary of Net Accounts Receivable Greater Than or Equal to 10% of Net Account Receivable Balance (Detail) (Accounts Receivable, Credit Concentration Risk)	3 Months Ended		12 Months Ended
	Oct. 31, 2014		Jul. 31, 2014
Philips	'		'
Accounts Receivable [Line Items]	'		'
Percentage of net accounts receivable	15.00%		16.00%
L-3	'		'
Accounts Receivable [Line Items]	'		'
Percentage of net accounts receivable	14.00%		16.00%
Toshiba	'		'
Accounts Receivable [Line Items]	'		'
Percentage of net accounts receivable	'	[1]	11.00%
[1]	Total net accounts receivable due from client was less than 10% in this period.

Summary_of_Net_Accounts_Receiv1

Summary of Net Accounts Receivable Greater Than or Equal to 10% of Net Account Receivable Balance (Parenthetical) (Detail) (Maximum, Largest customers, Toshiba, Accounts Receivable)	3 Months Ended
	Oct. 31, 2014
Maximum | Largest customers | Toshiba | Accounts Receivable	'
Accounts Receivable [Line Items]	'
Percentage of net accounts receivable	10.00%

Components_of_Inventory_Detail

Components of Inventory (Detail) (USD $)	Oct. 31, 2014	Jul. 31, 2014
Inventory [Line Items]	'	'
Raw materials	$64,700,000	$59,600,000
Work in process	45,600,000	41,200,000
Finished goods	26,300,000	24,000,000
Total inventory	$136,570,000	$124,777,000

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended
	Dec. 31, 2013	Oct. 31, 2014	Oct. 31, 2013	Jul. 31, 2014
Goodwill and Intangible Assets Disclosure [Line Items]	'	'	'	'
Goodwill	'	$57,589,000	'	$56,955,000
Acquisition of goodwill	'	600,000	'	'
Non-Amortizable Trade names, cost	'	7,600,000	'	7,600,000
Amortization expense related to acquired intangible assets	'	2,200,000	1,900,000	'
Impairment for goodwill and other intangible assets with indefinite lives	$0	'	'	'
Minimum	'	'	'	'
Goodwill and Intangible Assets Disclosure [Line Items]	'	'	'	'
Intangible assets, estimated useful lives	'	'1 year	'	'
Maximum	'	'	'	'
Goodwill and Intangible Assets Disclosure [Line Items]	'	'	'	'
Intangible assets, estimated useful lives	'	'14 years	'	'

Other_Intangible_Assets_Detail

Other Intangible Assets (Detail) (USD $)	3 Months Ended
	Oct. 31, 2014		Jul. 31, 2014
Intangible Assets by Major Class [Line Items]	'		'
Cost	$82,900,000		$82,000,000
Accumulated Amortization	26,800,000		24,600,000
Net	56,116,000		57,366,000
Developed technologies	'		'
Intangible Assets by Major Class [Line Items]	'		'
Weighted-Average Amortization Period	'10 years		'
Cost	30,200,000		29,600,000
Accumulated Amortization	9,800,000		9,000,000
Net	20,400,000		20,600,000
Customer relationships	'		'
Intangible Assets by Major Class [Line Items]	'		'
Weighted-Average Amortization Period	'13 years		'
Cost	44,100,000		43,900,000
Accumulated Amortization	16,400,000		15,100,000
Net	27,700,000		28,800,000
Tradenames	'		'
Intangible Assets by Major Class [Line Items]	'		'
Weighted-Average Amortization Period	'3 years	[1]	'
Cost	8,600,000		8,500,000
Accumulated Amortization	600,000		500,000
Net	$8,000,000		$8,000,000
[1]	$7.6 Million of Trade names are Non-amortizable

Other_Intangible_Assets_Parent

Other Intangible Assets (Parenthetical) (Detail) (USD $)	Oct. 31, 2014	Jul. 31, 2014
In Millions, unless otherwise specified
Intangible Assets by Major Class [Line Items]	'	'
Non-Amortizable Trade names, cost	$7.60	$7.60

Estimated_Future_Amortization_

Estimated Future Amortization Expense Related to Intangible Assets (Detail) (USD $)	Oct. 31, 2014
In Millions, unless otherwise specified
Finite Lived Intangible Assets Future Amortization Expense [Line Items]	'
2015 (remaining nine months)	$6.60
2016	7.9
2017	7.2
2018	6.2
2019	5
Thereafter	15.6
Finite-Lived Intangible Assets, Net, Total	$48.50

Assets_and_Liabilities_Carried

Assets and Liabilities Carried at Fair Value Measured on Recurring Basis (Detail) (Fair Value, Measurements, Recurring, USD $)	Oct. 31, 2014	Jul. 31, 2014
In Millions, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Plan assets for deferred compensation	$3.80	$3.60
Total assets at fair value	3.8	3.6
Contingent consideration	2.1	2.1
Total liabilities at fair value	2.1	2.1
Quoted Prices in Active Markets (Level 1)	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Plan assets for deferred compensation	3.8	3.6
Total assets at fair value	3.8	3.6
Significant Unobservable Inputs (Level 3)	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Contingent consideration	2.1	2.1
Total liabilities at fair value	$2.10	$2.10

Common_Stock_Repurchases_Addit

Common Stock Repurchases - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended	3 Months Ended	5 Months Ended
In Millions, except Share data, unless otherwise specified	Oct. 31, 2013	Dec. 08, 2011	Jul. 31, 2014	Oct. 31, 2014	Oct. 31, 2014	Jun. 02, 2014
	2011 Repurchase program	2011 Repurchase program	2011 Cumulative repurchase program	2014 Repurchase program	2014 Repurchase program	2014 Repurchase program
		Maximum				Maximum
Stockholders Equity Note [Line Items]	'	'	'	'	'	'
Amount authorized for repurchase of Company's common stock	'	$30	'	'	'	$30
Repurchase of common stock (in shares)	46,638	'	415,768	52,746	71,429	'
Repurchase of common stock	$3.70	'	$30	$3.70	$5.10	'
Average purchase price of common stock	$79.97	'	$71.98	$69.78	$71.46	'

Changes_in_Accumulated_Other_C

Changes in Accumulated Other Comprehensive Income (Detail) (USD $)	3 Months Ended			3 Months Ended
	Oct. 31, 2014	Oct. 31, 2014	Jul. 31, 2014	Oct. 31, 2014
		Unrealized Gains (Losses) on Pension Plan	Unrealized Gains (Losses) on Pension Plan	Currency Translation
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning balance	$7,805,000	($3,600,000)	($3,600,000)	$11,400,000
Pre-tax change before reclass to earnings	-3,500,000	'	'	-3,500,000
Income tax benefit (provision)	-100,000	'	'	-100,000
Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending balance	$4,175,000	($3,600,000)	($3,600,000)	$7,800,000

Sharebased_Compensation_Expens

Share-based Compensation Expense (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Oct. 31, 2014	Oct. 31, 2013
Compensation Related Costs Share Based Payments Disclosure [Line Items]	'	'
Share-based compensation expense before tax	$2.60	$2.70
Income tax effect	-0.8	-0.9
Share-based compensation expense included in net income (loss)	1.8	1.8
Cost of product sales	'	'
Compensation Related Costs Share Based Payments Disclosure [Line Items]	'	'
Share-based compensation expense before tax	0.2	0.2
Cost of Engineering Sales	'	'
Compensation Related Costs Share Based Payments Disclosure [Line Items]	'	'
Share-based compensation expense before tax	'	0.1
Research and Product Development	'	'
Compensation Related Costs Share Based Payments Disclosure [Line Items]	'	'
Share-based compensation expense before tax	0.7	0.6
Selling and Marketing	'	'
Compensation Related Costs Share Based Payments Disclosure [Line Items]	'	'
Share-based compensation expense before tax	0.3	0.3
General and Administrative	'	'
Compensation Related Costs Share Based Payments Disclosure [Line Items]	'	'
Share-based compensation expense before tax	$1.40	$1.50

Fair_Value_of_Option_Grant_Ass

Fair Value of Option Grant Assumptions (Detail) (USD $)	3 Months Ended
	Oct. 31, 2014		Oct. 31, 2013
Stock Options	'		'
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]	'		'
Expected option term in years	'5 years 3 months 22 days	[1]	'5 years 4 months 13 days	[1]
Expected volatility	29.30%	[2]	38.60%	[2]
Risk-free interest rate	1.83%	[3]	1.77%	[3]
Expected annual dividend yield	0.56%	[4]	0.52%	[4]
Total Shareholders Return	'		'
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]	'		'
Stock Price	71.09	[5]	77.08	[5]
Expected volatility	29.40%	[6]	27.60%	[6]
Risk-free interest rate	1.01%	[7]	0.82%	[7]
Expected annual dividend yield	0.00%	[8]	0.00%	[8]
[1]	The expected option term was estimated using historical data.
[2]	The expected volatility for each grant is determined based on the review of the average of historical daily price changes of our common stock over the expected option term.
[3]	The risk-free interest rate is determined based on the yield of the zero-coupon U.S. Treasury securities for a period that is commensurate with the expected term assumption.
[4]	The expected annual dividend yield is calculated by dividing the expected annual dividends by the stock price on the date of grant.
[5]	The stock price is the closing price of our common stock on the date of grant.
[6]	The expected volatility for each grant is determined based on the historical volatility for the peer group companies and our common stock over a period equal to the remaining term of the performance period from the date of grant for all awards.
[7]	The risk-free interest rate is determined based on the yield of zero-coupon U.S. Treasury securities for a period that is commensurate with the expected term assumption.
[8]	Dividends are considered reinvested when calculating TSR. The dividend yield is therefore considered to be 0%.

Sharebased_Compensation_Additi

Share-based Compensation - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Oct. 31, 2014	Oct. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Intrinsic value of options exercised	$0.10	$1.50
Total fair value of restricted stock grants vested in period	5.2	19.8
Stock Option and Restricted Stock Bonus Plans	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Unrecognized compensation cost related to non-vested share-based compensation arrangements	$17	'
Unrecognized compensation cost related to non-vested share-based compensation arrangements, weighted average period	'1 year 10 months 24 days	'
Time Based Restricted Stock Awards	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Weighted average grant date fair value of awards granted	$71.09	$76.99
Non-GAAP EPS Performance-Based Awards	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options, grants in period	34,850	35,562
Stock Options	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Weighted average grant date fair value of awards granted	$19.95	$27.54
Total Shareholders Return	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options, grants in period	27,065	27,355
Performance Based Restricted Stock Awards	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Weighted average grant date fair value of awards granted	$78.25	$93.76

Fair_Value_of_Option_Grant_Ass1

Fair Value of Option Grant Assumptions (Parenthetical) (Detail) (Total Shareholders Return)	3 Months Ended
	Oct. 31, 2014		Oct. 31, 2013
Total Shareholders Return	'		'
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]	'		'
Expected annual dividend yield	0.00%	[1]	0.00%	[1]
[1]	Dividends are considered reinvested when calculating TSR. The dividend yield is therefore considered to be 0%.

Restructuring_Charges_Addition

Restructuring Charges - Additional Information (Detail) (USD $)	3 Months Ended
	Oct. 31, 2014	Oct. 31, 2013	Oct. 31, 2014	Jul. 31, 2014
			Fiscal Year 2013 Restructuring Plan	Fiscal Year 2014 Restructuring Plan
			Employee	Employee
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring charges	($58,000)	($39,000)	($100,000)	$2,900,000
Involuntarily terminated employees	'	'	115	48
Restructuring charges incurred to date	'	'	$4,000,000	'

Summary_of_Charges_Related_to_

Summary of Charges Related to Accrued Restructuring Activity (Detail) (USD $)

3 Months Ended

3 Months Ended

Oct. 31, 2014

Oct. 31, 2013

Oct. 31, 2014

Oct. 31, 2013

Oct. 31, 2014

Oct. 31, 2013

Jul. 31, 2013

Oct. 31, 2014

Oct. 31, 2013

Oct. 31, 2013

Employee Severance and Benefits

Employee Severance and Benefits

Facility Exit Costs

Facility Exit Costs

Facility Exit Costs

Acquisition Related Charges

Acquisition Related Charges

Restructuring Costs

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

Balance at beginning period

$3,800,000

$2,800,000

[1]

$2,900,000

[2]

$1,800,000

$800,000

[3]

$200,000

$200,000

$100,000

[3]

$800,000

'

Restructuring Charge

58,000

39,000

'

200,000

'

'

'

'

100,000

300,000

[1]

Adjustments

-100,000

-300,000

[1]

'

-200,000

-100,000

[3]

'

'

'

-100,000

'

Cash payments

-1,100,000

-600,000

[1]

-900,000

[2]

-500,000

-100,000

[3]

'

'

-100,000

[3]

-100,000

'

Balance at end period

$2,600,000

$2,200,000

[1]

$2,000,000

[2]

$1,300,000

$600,000

[3]

$200,000

$200,000

'

$700,000

'

[1]

All activity during the period pertains to the 2013 Restructuring Plan.

[2]

All activity during the period pertains to the 2014 Restructuring Plan.

[3]

All activity pertains to the 2013 Restructuring Plan.

Location_of_Restructuring_Char

Location of Restructuring Charges Comprised on Consolidated Balance Sheets (Detail) (USD $)	Oct. 31, 2014	Jul. 31, 2014	Oct. 31, 2013		Jul. 31, 2013
In Millions, unless otherwise specified
Restructuring Cost and Reserve [Line Items]	'	'	'		'
Restructuring and related charges	$2.60	$3.80	$2.20	[1]	$2.80	[1]
Accrued Restructuring Charges	'	'	'		'
Restructuring Cost and Reserve [Line Items]	'	'	'		'
Restructuring and related charges	2.3	3.4	'		'
Other long-term liabilities	'	'	'		'
Restructuring Cost and Reserve [Line Items]	'	'	'		'
Restructuring and related charges	$0.30	$0.40	'		'
[1]	All activity during the period pertains to the 2013 Restructuring Plan.

Restructuring_and_Related_Char

Restructuring and Related Charges by Segment (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Oct. 31, 2014	Oct. 31, 2013
Restructuring Cost and Reserve [Line Items]	'	'
Restructuring and related charges, net	($0.10)	'
Medical Imaging	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Restructuring and related charges, net	'	-0.1
Ultrasound	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Restructuring and related charges, net	($0.10)	$0.10

Computation_of_Basic_and_Dilut

Computation of Basic and Diluted Net Income (Loss) Per Share (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Oct. 31, 2014		Oct. 31, 2013
Schedule of Earnings Per Share, Basic and Diluted, by Common Class [Line Items]	'		'
Net income (loss)	$3,654		($3,775)
Weighted average number of common shares outstanding-basic	12,407		12,443
Effect of dilutive securities:	'		'
Stock options and restricted stock units	163		'
Weighted average number of common shares outstanding-diluted	12,570		12,443
Basic net income (loss) per share:	$0.29		($0.30)
Diluted net income (loss) per share:	$0.29		($0.30)
Anti-dilutive shares related to outstanding stock options and unvested restricted stock	255	[1]	546	[1]
[1]	These shares related to outstanding stock options and unvested restricted stock were not included in our calculations of diluted earnings per share, as the effect of including them would be anti-dilutive.

Provision_for_Benefit_from_Inc

Provision for (Benefit from) Income Taxes and Effective Tax Rate (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2014	Oct. 31, 2013
Provision For Income Taxes [Line Items]	'	'
Provision for (benefit from) income taxes	$1,421	($2,011)
Effective tax rate	28.00%	35.00%

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Oct. 31, 2014	Jul. 31, 2014
Income Taxes [Line Items]	'	'
U.S. Federal statutory tax rate	35.00%	'
Unrecognized tax benefits, accrued interest and penalties	$0.70	$0.60
Unrecognized tax benefits, for uncertain tax positions	$6.90	'

Segment_Information_Additional

Segment Information - Additional Information (Detail)	3 Months Ended
	Oct. 31, 2014
	Segment
Segment Reporting Information [Line Items]	'
Number of segments	3

Reportable_Segment_Information

Reportable Segment Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2014		Oct. 31, 2013	Jul. 31, 2014
Product Revenue:	'		'	'
Product Revenue	$116,935		$108,454	'
Engineering Revenue:	'		'	'
Engineering Revenue	1,381		1,628	'
Net Revenue:	'		'	'
Total net revenue	118,316		110,082	'
Income (loss) before income taxes:	'		'	'
Income (loss) from operations	4,957		-5,365	'
Total other (expense) income, net	118		-421	'
Income (loss) before income taxes	5,075		-5,786	'
Identifiable assets by segment:	'		'	'
Assets	603,316		'	614,342
Goodwill by segment:	'		'	'
Goodwill	57,589		'	56,955
Reportable segments	'		'	'
Identifiable assets by segment:	'		'	'
Assets	481,900		'	489,000
Corporate	'		'	'
Identifiable assets by segment:	'		'	'
Assets	121,400	[1]	'	125,300	[1]
Medical Imaging	'		'	'
Product Revenue:	'		'	'
Product Revenue	66,300		59,200	'
Engineering Revenue:	'		'	'
Engineering Revenue	400		1,000	'
Net Revenue:	'		'	'
Total net revenue	66,700		60,200	'
Income (loss) before income taxes:	'		'	'
Income (loss) from operations	7,400		-500	'
Medical Imaging | Reportable segments	'		'	'
Identifiable assets by segment:	'		'	'
Assets	207,200		'	218,500
Goodwill by segment:	'		'	'
Goodwill	1,900		'	1,900
Ultrasound	'		'	'
Product Revenue:	'		'	'
Product Revenue	37,300		34,700	'
Engineering Revenue:	'		'	'
Engineering Revenue	500		'	'
Net Revenue:	'		'	'
Total net revenue	37,800		34,700	'
Income (loss) before income taxes:	'		'	'
Income (loss) from operations	-3,000		-4,000	'
Ultrasound | Reportable segments	'		'	'
Identifiable assets by segment:	'		'	'
Assets	240,300		'	235,500
Goodwill by segment:	'		'	'
Goodwill	55,100		'	55,100
Security and Detection	'		'	'
Product Revenue:	'		'	'
Product Revenue	13,300		14,600	'
Engineering Revenue:	'		'	'
Engineering Revenue	500		600	'
Net Revenue:	'		'	'
Total net revenue	13,800		15,200	'
Income (loss) before income taxes:	'		'	'
Income (loss) from operations	600		-900	'
Goodwill by segment:	'		'	'
Goodwill	600	[2]	'	'
Security and Detection | Reportable segments	'		'	'
Identifiable assets by segment:	'		'	'
Assets	$34,400		'	$35,000
[1]	Includes cash and cash equivalents of $57.1 million and $60.9 million as of October 31, 2014 and July 31, 2014, respectively.
[2]	Includes goodwill related to the acquisition of Pathfinder.

Reportable_Segment_Information1

Reportable Segment Information (Parenthetical) (Detail) (USD $)	Oct. 31, 2014	Jul. 31, 2014	Oct. 31, 2013	Jul. 31, 2013
In Thousands, unless otherwise specified
Segment Reporting Information [Line Items]	'	'	'	'
Cash and cash equivalents	$116,443	$114,540	$105,076	$113,033
Corporate	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Cash and cash equivalents	$57,100	$60,900	'	'

Guarantees_Commitments_and_Con2

Guarantees, Commitments and Contingencies - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

3 Months Ended

0 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

Oct. 11, 2011

Oct. 31, 2014

Oct. 31, 2013

Oct. 31, 2014

Jul. 31, 2014

Oct. 31, 2014

Jul. 31, 2014

Oct. 11, 2011

Oct. 31, 2014

Jul. 31, 2014

Oct. 11, 2011

Oct. 31, 2014

Oct. 31, 2014

Oct. 11, 2011

Oct. 31, 2014

Oct. 11, 2011

Oct. 11, 2011

Oct. 31, 2014

Oct. 11, 2011

Oct. 31, 2014

Oct. 11, 2011

Oct. 11, 2011

Oct. 11, 2011

Product Extended Warranty Contracts

Product Extended Warranty Contracts

Other Liabilities

Other Liabilities

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Minimum

Minimum

Minimum

Minimum

Minimum

Maximum

Maximum

Maximum

Maximum

Maximum

Maximum

Other Revolving Credit Facilities

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

LIBOR Rate

Base Rate

LIBOR Rate

Base Rate

Commitments and Contingencies Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Liabilities related to agreements

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Standard product warranty term

'

'

'

'

'

'

'

'

'

'

'

'

'12 months

'

'

'

'

'60 months

'

'

'

'

'

Deferred revenue for product extended warranty contracts

'

'

'

6,600,000

7,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revolving credit agreement period

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit facility maximum borrow capacity

'

'

'

'

'

'

'

'

'

'

100,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Credit facility, expiry date

'

'

'

'

'

'

'

10-Oct-16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate available credit amount under specified circumstances

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000,000

'

'

Percentage of capital stock pledge as collateral

'

'

'

'

'

'

'

'

'

'

65.00%

'

'

'

'

'

'

'

'

'

'

'

'

Variable interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.25%

0.00%

'

'

'

'

2.00%

1.00%

Credit facility commitment fee percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

0.20%

'

'

'

'

0.35%

'

'

'

'

Leverage ratio of total debt to earnings before interest, taxes, depreciation, and amortization or EBITDA

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

275.00%

'

'

'

Interest coverage ratio

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300.00%

'

'

'

'

'

'

'

'

Leverage ratio

'

'

'

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit facility transaction costs incurred

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit facility, maturity period

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit facility available borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

1,400,000

'

'

'

'

'

'

'

'

'

'

'

Line of credit amount outstanding

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

Asset retirement obligations, estimated cost of restoring our leased facilities

'

'

'

'

'

1,100,000

1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business exit cost

'

$800,000

$300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Product_Warranty_Liability_Det

Product Warranty Liability (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Oct. 31, 2014
Product Liability Contingency [Line Items]	'
Product warranty liability, beginning balance	$6
Provision	1.3
Settlements made in cash or in kind during the period	-1.1
Product warranty liability, ending balance	$6.20

Subsequent_Event_Additional_In

Subsequent Event - Additional Information (Detail) (Subsequent Event, USD $)	0 Months Ended
	Dec. 05, 2014
Subsequent Event	'
Subsequent Event [Line Items]	'
Dividend declaration date	5-Dec-14
Dividend declared	$0.10
Dividend payable date	2-Jan-15
Dividend record date	19-Dec-14